Evoke Pharma, Inc. (EVOK)
Dec 17, 2025 - EVOK was delisted (reason: acquired by QOL Medical)
11.00
+0.04 (0.36%)
Inactive · Last trade price on Dec 16, 2025
Evoke Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 11.58 | 13.6 | 4.74 | 9.84 | 9.14 | 8.07 |
Cash & Short-Term Investments | 11.58 | 13.6 | 4.74 | 9.84 | 9.14 | 8.07 |
Cash Growth | 2.09% | 186.88% | -51.85% | 7.64% | 13.33% | 42.46% |
Receivables | 3.19 | 2.42 | 0.67 | 0.62 | 0.3 | 0.02 |
Inventory | 0.6 | 0.45 | 0.48 | 0.29 | 0.19 | 0.24 |
Prepaid Expenses | 0.14 | 0.73 | 0.89 | 0.95 | 0.92 | 0.92 |
Other Current Assets | 0.03 | 0.04 | 0.05 | 0.01 | 0.01 | 0.03 |
Total Current Assets | 15.54 | 17.24 | 6.83 | 11.72 | 10.56 | 9.28 |
Property, Plant & Equipment | 0.11 | 0.15 | - | 0.13 | 0.01 | 0.14 |
Long-Term Deferred Charges | - | 0.12 | 0.24 | - | - | - |
Other Long-Term Assets | 0.01 | 0.01 | - | - | - | 0.01 |
Total Assets | 15.65 | 17.52 | 7.07 | 11.85 | 10.57 | 9.43 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 3.52 | 2.04 | 1.61 | 0.87 | 0.87 | 1.27 |
Accrued Expenses | 3.46 | 3.18 | 2.94 | 0.59 | 0.52 | 1.02 |
Short-Term Debt | - | - | - | - | - | 0.1 |
Current Portion of Long-Term Debt | 5 | 5 | 5 | - | - | - |
Current Portion of Leases | 0.07 | 0.06 | - | 0.13 | 0.01 | 0.14 |
Other Current Liabilities | 0.2 | 0.1 | 0.1 | 0.07 | - | 5 |
Total Current Liabilities | 12.24 | 10.38 | 9.65 | 1.65 | 1.41 | 7.54 |
Long-Term Debt | - | - | - | 5 | 5 | 5 |
Long-Term Leases | 0.05 | 0.1 | - | - | - | - |
Other Long-Term Liabilities | - | - | - | 1.11 | 0.61 | 0.11 |
Total Liabilities | 12.29 | 10.48 | 9.65 | 7.77 | 7.02 | 12.65 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 136.19 | 135.83 | 120.86 | 119.73 | 110.98 | 95.67 |
Retained Earnings | -132.82 | -128.79 | -123.44 | -115.65 | -107.42 | -98.89 |
Shareholders' Equity | 3.36 | 7.04 | -2.58 | 4.08 | 3.56 | -3.21 |
Total Liabilities & Equity | 15.65 | 17.52 | 7.07 | 11.85 | 10.57 | 9.43 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 5.11 | 5.16 | 5 | 5.13 | 5.01 | 5.25 |
Net Cash (Debt) | 6.46 | 8.44 | -0.26 | 4.71 | 4.13 | 2.82 |
Net Cash Growth | 1.97% | - | - | 14.09% | 46.38% | -48.91% |
Net Cash Per Share | 2.32 | 4.43 | -0.94 | 18.00 | 18.49 | 15.95 |
Filing Date Shares Outstanding | 2.16 | 2.02 | 0.71 | 0.28 | 0.23 | 0.22 |
Total Common Shares Outstanding | 2.16 | 2.01 | 0.28 | 0.28 | 0.23 | 0.18 |
Working Capital | 3.3 | 6.86 | -2.82 | 10.07 | 9.15 | 1.75 |
Book Value Per Share | 1.56 | 3.49 | -9.26 | 14.66 | 15.68 | -17.39 |
Tangible Book Value | 3.36 | 7.04 | -2.58 | 4.08 | 3.56 | -3.21 |
Tangible Book Value Per Share | 1.56 | 3.49 | -9.26 | 14.66 | 15.68 | -17.39 |